Treatment of Autoimmune Hepatitis

First-Line Treatment Regimen

• The European Association for the Study of the Liver recommends starting prednisone first, then adding azathioprine after 2 weeks, particularly when bilirubin is below 6 mg/dL, as a safer approach in patients with severe hyperbilirubinemia 1
• Budesonide 9 mg/day plus azathioprine may be used specifically in treatment-naive, non-cirrhotic patients with early-stage disease who face high risk of steroid side effects, according to the European Association for the Study of the Liver 1

Treatment Goals and Monitoring

• The European Association for the Study of the Liver states that complete normalization of BOTH serum aminotransferases AND IgG levels must be the treatment goal, as persistent elevations predict relapse, ongoing histological activity, progression to cirrhosis, and poor outcomes 1
• Normal liver tests are achieved in 66-91% of treated patients within 2 years, with average duration to normalization being 19 months, as reported by the American Gastroenterological Association 2

Management of Special Situations

• The European Association for the Study of the Liver recommends treating acute severe autoimmune hepatitis immediately with high-dose intravenous corticosteroids (≥1 mg/kg) as early as possible 1
• If no improvement occurs within 7 days, the European Association for the Study of the Liver suggests listing for emergency liver transplantation 1

Non-Response or Treatment Failure

• The American Gastroenterological Association recommends increasing to high-dose therapy: prednisone 60 mg daily alone OR prednisone 30 mg daily plus azathioprine 150 mg daily for at least 1 month in confirmed non-responders 2
• The American Gastroenterological Association suggests using alternative second-line agents for steroid-refractory cases, including Tacrolimus, Cyclosporine, and Mycophenolate mofetil 3

Long-Term Management and Relapse

• The American Gastroenterological Association reports that relapse occurs in 50-90% of patients within 12 months of stopping treatment, even after achieving complete biochemical and histological remission 2
• Only 20-28% achieve sustained remission off therapy, according to the American Gastroenterological Association 2

Prevention of Treatment Complications

• The American Association for the Study of Liver Diseases recommends minimizing cumulative steroid exposure to reduce the risk of severe complications, such as osteoporosis, vertebral compression, diabetes, cataracts, hypertension, and psychosis 4

Initial Treatment for Autoimmune Hepatitis

Standard Treatment Regimens for Adults

• The American Association for the Study of Liver Diseases recommends a combination of prednisone (or prednisolone) plus azathioprine as the initial treatment for autoimmune hepatitis, which is associated with fewer corticosteroid-related side effects than prednisone monotherapy (10% versus 44%) 5, 6
• The initial dose of prednisone is 30 mg/day, reducing to 10 mg/day over 4 weeks, plus azathioprine 1 mg/kg/day, and this regimen should be continued for at least 2 years and for at least 12 months after normalization of liver enzymes 6, 7, 8

Dosing Schedule for Combination Therapy

• The dosing schedule for combination therapy is as follows: Week 1: Prednisone 30 mg/day + Azathioprine 50 mg/day (US) or 1-2 mg/kg/day (Europe), Week 2: Prednisone 20 mg/day + Azathioprine (same dose), Week 3-4: Prednisone 15 mg/day + Azathioprine (same dose), and Maintenance: Prednisone 10 mg/day + Azathioprine (same dose) until endpoint 5, 9

Monitoring Response

• The response to treatment should be assessed by 4-8 weeks after treatment initiation, and if a positive biochemical response is observed, prednisone should be tapered to 5-10 mg daily over the next 6 months while maintaining azathioprine 10

Special Considerations

• For patients with cytopenia, consider measuring thiopurine methyltransferase (TPMT) activity before starting azathioprine to exclude homozygote TPMT deficiency, and prednisone monotherapy is appropriate for patients with severe pre-treatment cytopenia 6, 7, 9, 11
• For non-responding patients, consider higher doses of steroids combined with azathioprine 2 mg/kg/day, and alternative options include tacrolimus or cyclosporine for steroid-refractory cases 6, 7, 12

Treatment Endpoints and Long-Term Management

• Treatment should continue until remission, which is defined as normal laboratory indices and resolution of liver inflammation on biopsy, and the average duration of initial treatment is 18-24 months 11
• Relapse occurs in 50-90% of patients within 12 months of stopping treatment, and after relapse, consider long-term maintenance with azathioprine 2 mg/kg/day 8, 13

Prevention of Treatment Complications

• All patients should receive calcium and vitamin D supplementation, and bone mineral density should be monitored with DEXA scanning at 1-2 year intervals 5, 6, 7
• Vaccination against hepatitis A and B should be performed early in susceptible patients 8

Treatment of Autoimmune Hepatitis

First-Line Treatment Regimen

• The American Association for the Study of Liver Diseases recommends starting combination therapy with prednisone (or prednisolone) 30 mg/day plus azathioprine 1-2 mg/kg/day immediately in treatment-naïve patients without cirrhosis, acute severe hepatitis, or acute liver failure 14
• Budesonide 9 mg/day plus azathioprine may be used specifically in treatment-naïve, non-cirrhotic patients with early-stage disease who face high risk of steroid side effects, as recommended by the American Association for the Study of Liver Diseases 14

Pre-Treatment Considerations

• The American Association for the Study of Liver Diseases recommends testing for thiopurine methyltransferase (TPMT) activity before starting azathioprine to exclude homozygote TPMT deficiency, which predisposes to severe myelosuppression 14

Special Clinical Situations

• The American Association for the Study of Liver Diseases recommends immediately starting high-dose intravenous prednisolone (≥1 mg/kg) as early as possible for acute severe autoimmune hepatitis, and listing for emergency liver transplantation if no improvement occurs within 7 days 14
• Azathioprine can be continued throughout pregnancy, whereas mycophenolate mofetil is contraindicated, as recommended by the American Association for the Study of Liver Diseases 14
• Prednisone is generally safe during pregnancy, as recommended by the American Association for the Study of Liver Diseases 14

Long-Term Management After Remission

• Liver tissue examination prior to drug withdrawal in individuals with ≥2 years of biochemical remission is preferred but not mandatory in adults and required in children, as recommended by the American Association for the Study of Liver Diseases 14
• The American Association for the Study of Liver Diseases recommends considering mycophenolate mofetil (MMF) or tacrolimus as second-line treatment in patients who fail first-line therapy 14
• The American Association for the Study of Liver Diseases recommends using standard prednisone/prednisolone plus azathioprine combination instead of budesonide in cirrhotic patients due to impaired first-pass metabolism 14
• Consider elastography (FibroScan) to detect disease reactivation or progressive fibrosis, as recommended by the American Association for the Study of Liver Diseases 14

Management and Monitoring of Autoimmune Hepatitis

Initial Treatment and Pre‑Therapy Requirements

Treatment Goals

Monitoring Schedule

Bone‑Health and Supplementation

Steroid‑Related Adverse Effects

Azathioprine‑Related Adverse Effects

Relapse and Maintenance Therapy

Lifestyle Recommendations

Warning Signs Requiring Immediate Attention

Prognosis

Long‑Term Follow‑Up

Guideline Recommendations for Autoimmune Hepatitis‑Associated Cirrhosis

Treatment Initiation

• Initiate combination immunosuppressive therapy (prednisone 30 mg daily plus azathioprine 1–2 mg/kg daily) immediately in patients with cirrhosis, as this regimen induces remission in 80‑90 % of cases, can reverse fibrosis and cirrhosis, and markedly improves survival even when cirrhosis is already established. [20][21]

Pre‑treatment Assessment

• Perform thiopurine methyltransferase (TPMT) testing before starting azathioprine to identify homozygous deficiency, which markedly increases the risk of severe myelosuppression. 21

Maintenance Therapy

• After biochemical remission, continue azathioprine at 2 mg/kg daily indefinitely as maintenance monotherapy while tapering prednisone to the lowest effective dose or discontinuing it altogether. 21

Surveillance for Hepatocellular Carcinoma

• Conduct hepatic ultrasonography every six months in all cirrhotic patients, regardless of disease control, to detect hepatocellular carcinoma at an early stage. 21

Liver Transplantation Evaluation

• Refer patients for liver transplantation evaluation when any of the following occur:

• Post‑transplant outcomes show a five‑year survival rate of 75‑92 % and a ten‑year survival rate of approximately 75 %. Recurrent autoimmune hepatitis occurs in about 30 % of recipients, typically presenting as a mild, manageable disease. 21

Contraindications and Pitfalls

• Do not withhold immunosuppressive therapy solely because cirrhosis is present; cirrhosis is an indication for treatment, not a contraindication. 20
• Avoid the use of interferon‑α in patients with decompensated cirrhosis, as it can precipitate worsening liver injury. 22
• Ensure ongoing HCC surveillance (ultrasound every 6 months) even when disease activity is controlled. 21

First‑Line and Subsequent Management of Autoimmune Hepatitis

First‑Line Therapy

• The American Association for the Study of Liver Diseases recommends initiating combination therapy with prednisone 30 mg/day plus azathioprine 50 mg/day (or 1–2 mg/kg/day) because this regimen achieves biochemical remission in approximately 80 % of patients within 6 months and produces far fewer corticosteroid‑related adverse events (10 % vs 44 %) compared with prednisone alone【23】【24】【25】.
• The standard tapering schedule is: week 1 – prednisone 30 mg/day + azathioprine (dose as above); week 2 – prednisone 20 mg/day + azathioprine unchanged; weeks 3‑4 – prednisone 15 mg/day + azathioprine unchanged; thereafter taper prednisone to ≤10 mg/day while maintaining azathioprine until the predefined treatment endpoint【23】【25】.
• TPMT activity should be measured before starting azathioprine to identify patients with homozygous deficiency who are at high risk for severe myelosuppression【25】.
• In patients presenting with severe hyperbilirubinemia, prednisone should be started first and azathioprine added after 2 weeks once bilirubin improves【25】.
• Azathioprine must be withheld in patients with severe pretreatment cytopenia (white‑blood‑cell count < 2.5 × 10⁹/L or platelet count < 50 × 10⁹/L)【23】.

Alternative First‑Line Option (Budesonide)

• For treatment‑naïve, non‑cirrhotic patients with early‑stage disease who are at high risk for major steroid‑related side effects, budesonide 9 mg/day plus azathioprine is an acceptable alternative【24】【25】.
• This budesonide‑based regimen produces faster normalization of transaminases and a lower side‑effect burden than standard prednisone‑based therapy in non‑cirrhotic patients【24】.

Treatment Goals and Monitoring

• The therapeutic target is complete normalization of both serum aminotransferases (ALT/AST) and IgG levels; persistent elevation of either marker predicts relapse, ongoing histologic activity, progression to cirrhosis, and poorer outcomes【25】.

Management of Treatment Failure or Suboptimal Response

• If the diagnosis is confirmed and adherence verified, escalation to high‑dose therapy (prednisone 60 mg/day alone or prednisone 30 mg/day + azathioprine 150 mg/day, up to 2 mg/kg/day) for at least 1 month is recommended【23】【26】.
• After one month of high‑dose therapy, prednisone should be reduced by 10 mg and azathioprine by 50 mg each month as clinical and laboratory parameters improve【26】.
• Persistent non‑response should prompt reconsideration of the diagnosis and verification of medication adherence【25】.

Second‑Line Agents for Refractory Disease

• Mycophenolate mofetil (2 g daily) yields favorable outcomes in roughly 47 % of steroid‑refractory patients, particularly those intolerant to azathioprine【27】.

Acute Severe Autoimmune Hepatitis

• Immediate treatment with high‑dose intravenous corticosteroids (≥1 mg/kg) is advised for acute severe disease【25】.
• If no biochemical or MELD improvement is observed within 7 days, patients should be listed for emergency liver transplantation【25】.
• Younger, non‑Caucasian patients presenting with acute or fulminant disease and confluent necrosis on biopsy have a higher risk of treatment failure【25】.

Relapse Management

• Relapse occurs in 50–90 % of patients within 12 months after cessation of therapy, even after complete biochemical and histologic remission【25】.
• After the first relapse, the original regimen (prednisone + azathioprine) should be reinstated【26】.
• After multiple relapses, long‑term maintenance with azathioprine 2 mg/kg/day while tapering prednisone to the lowest effective dose—or discontinuing it—is recommended【26】.
• In long‑term azathioprine maintenance, 87 % of adults remain in remission over a median follow‑up of 67 months【26】; withdrawal arthralgia occurs in 63 % but is usually manageable【26】.
• Monitoring should include surveillance for myelosuppression (≈7 %) and lymphopenia (≈57 %)【26】.

Special Populations

Children

• All children with confirmed autoimmune hepatitis should receive treatment because the disease is more severe at presentation and treatment delays worsen long‑term outcomes【23】.
• More than 50 % of pediatric patients present with cirrhosis【23】.

Liver Transplantation

• Referral for transplantation evaluation is indicated when MELD ≥ 15, decompensated cirrhosis persists despite optimal immunosuppression, or hepatocellular carcinoma meeting transplant criteria develops【27】.
• Recurrent autoimmune hepatitis after transplant is managed with prednisone + azathioprine (dose‑adjusted) or with increased corticosteroids combined with optimized calcineurin‑inhibitor therapy (preferably tacrolimus)【27】.
• If the response remains incomplete, mycophenolate mofetil (2 g daily) should be added to the corticosteroid + calcineurin‑inhibitor regimen【27】.

Contraindications and Pitfalls

• Immunosuppressive therapy should not be started in patients with minimal or inactive disease activity or inactive cirrhosis; these patients should instead be followed closely every 3–6 months【23】.
• Treatment should be avoided in patients with serious pre‑existing comorbidities (e.g., severe osteoporosis, uncontrolled diabetes, psychosis, brittle hypertension) unless the liver disease is severe, progressive, and the comorbidities can be adequately controlled【23】.
• Partial biochemical improvement is insufficient; both transaminases and IgG must normalize completely before treatment is considered successful【25】.
• Azathioprine must not be initiated in patients with severe cytopenia without first assessing TPMT status【23】【25】.
• In acute severe disease that fails to improve within 7 days of high‑dose corticosteroids, transplantation listing should not be delayed【25】.

Level of evidence: not explicitly graded in the cited sources.